News
Jacobio Pharma submits phase I/II IND application for its BET inhibitor, JAB-8263 to treat autoimmune diseases to CDE in China: Beijing, Shanghai Friday, July 4, 2025, 13:00 Hrs [ ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback